Li Baisong, Ma Lin, Li Xiwen, Suleman Zainab, Liu Changming, Piskareva Olga, Liu Mi
Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu 215300, People's Republic of China; College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, People's Republic of China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China.
Kunshan Hospital of Traditional Chinese Medicine, Kunshan, Jiangsu 215300, People's Republic of China; College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215123, People's Republic of China; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China; Department of Anatomy and Regenerative Medicine, Tissue Engineering Research Group, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
J Control Release. 2024 Sep;373:823-836. doi: 10.1016/j.jconrel.2024.07.077. Epub 2024 Aug 3.
Precisely co-delivering antigens and immunosuppressants via nano/microcarriers to antigen-presenting cells (APCs) to induce antigen-specific immune tolerance represents a highly promising strategy for treating or preventing autoimmune diseases. The physicochemical properties of nano/microcarriers play a pivotal role in regulating immune function, with particle size and surface charge emerging as crucial parameters. In particular, very few studies have investigated micron-scale carriers of antigens. Herein, various nanoparticles and microparticles (NPs/MPs) with diverse particle sizes (ranging from 200 nm to 5 μm) and surface charges were prepared. Antigen peptides (MOG35-55) and immunosuppressants were encapsulated in these particles to induce antigen-specific immune tolerance. Two emulsifiers, PVA and PEMA, were employed to confer different surface charges to the NPs/MPs. The in vitro and in vivo studies demonstrated that NP/MP-PEMA could induce immune tolerance earlier than NP/MP-PVA and that NP/MP-PVA could induce immune tolerance more slowly and sustainably, indicating that highly negatively charged particles can induce immune tolerance more rapidly. Among the different sizes and charged particles tested, 200-nm-NP-PVA and 3-μm-MP-PEMA induced the greatest immune tolerance. In addition, the combination of NPs with MPs can further improve the induction of immune tolerance. In particular, combining 200 nm-NP-PVA with 3 μm-MP-PEMA or combining 500 nm-NP-PEMA with 3 μm-MP-PVA had optimal therapeutic efficacy. This study offers a new perspective for treating diseases by combining NPs with MPs and applying different emulsifiers to prepare NPs and MPs.
通过纳米/微载体将抗原和免疫抑制剂精确共递送至抗原呈递细胞(APC)以诱导抗原特异性免疫耐受,是治疗或预防自身免疫性疾病的一种极具前景的策略。纳米/微载体的物理化学性质在调节免疫功能中起着关键作用,粒径和表面电荷是关键参数。特别是,很少有研究调查微米级抗原载体。在此,制备了具有不同粒径(200纳米至5微米)和表面电荷的各种纳米颗粒和微米颗粒(NP/MP)。将抗原肽(MOG35-55)和免疫抑制剂包裹在这些颗粒中以诱导抗原特异性免疫耐受。使用两种乳化剂PVA和PEMA赋予NP/MP不同的表面电荷。体外和体内研究表明,NP/MP-PEMA比NP/MP-PVA能更早诱导免疫耐受,而NP/MP-PVA诱导免疫耐受的速度更慢且更持久,这表明高负电荷颗粒能更快诱导免疫耐受。在测试的不同尺寸和带电颗粒中,200纳米-NP-PVA和3微米-MP-PEMA诱导的免疫耐受最强。此外,NP与MP的组合可进一步提高免疫耐受的诱导效果。特别是,将200纳米-NP-PVA与3微米-MP-PEMA组合或将500纳米-NP-PEMA与3微米-MP-PVA组合具有最佳治疗效果。本研究为通过将NP与MP组合并应用不同乳化剂制备NP和MP来治疗疾病提供了新的视角。